See more : Hanison Construction Holdings Limited (0896.HK) Income Statement Analysis – Financial Results
Complete financial analysis of BioCardia, Inc. (BCDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioCardia, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BOL Bancshares Inc. PFD (BOLBP) Income Statement Analysis – Financial Results
- Sungmoon Electronics Co., Ltd. (014915.KS) Income Statement Analysis – Financial Results
- Ningbo Yunsheng Co., Ltd. (600366.SS) Income Statement Analysis – Financial Results
- Statera Biopharma, Inc. (STAB) Income Statement Analysis – Financial Results
- Engineer Gold Mines Ltd. (EGMLF) Income Statement Analysis – Financial Results
BioCardia, Inc. (BCDA)
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.00K | 1.35M | 1.02M | 145.00K | 710.00K | 625.00K | 479.00K | 576.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.87M | 1.27M | 643.00K | 0.00 | 0.00 | 0.00 | 3.76M | 4.08M | 3.96M | 3.87M | 3.99M | 4.20M | 3.80M | 3.40M | 3.15M |
| Cost of Revenue | 7.73M | 11.90M | 640.00K | 4.00K | 358.00K | 517.00K | 690.00K | 746.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 380.00K | 197.00K | 130.00K | 0.00 | 0.00 | 0.00 | 860.33K | 1.01M | 971.26K | 952.26K | 898.17K | 1.00M | 900.00K | 800.00K | 727.61K |
| Gross Profit | -7.25M | -10.55M | 375.00K | 141.00K | 352.00K | 108.00K | -211.00K | -170.00K | 517.00K | 427.00K | 268.00K | 62.00K | 12.00K | 0.00 | 1.49M | 1.07M | 513.00K | 0.00 | 0.00 | 0.00 | 2.90M | 3.07M | 2.99M | 2.91M | 3.09M | 3.20M | 2.90M | 2.60M | 2.42M |
| Gross Profit Ratio | -1,519.71% | -780.25% | 36.95% | 97.24% | 49.58% | 17.28% | -44.05% | -29.51% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 79.67% | 84.46% | 79.78% | 0.00% | 0.00% | 0.00% | 77.12% | 75.32% | 75.46% | 75.37% | 77.48% | 76.19% | 76.32% | 76.47% | 76.89% |
| Research & Development | 7.73M | 8.83M | 8.56M | 9.81M | 8.56M | 8.45M | 5.80M | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00M | 1.33M | 215.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73M | 0.00 | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.40M | 4.42M | 5.09M | 5.86M | 6.00M | 5.76M | 6.40M | 4.11M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 5.59M | 3.91M | 610.00K | 79.80K | 98.18K | 101.48K | 3.59M | 3.58M | 4.14M | 4.93M | 4.90M | 4.30M | 4.00M | 3.20M | 2.21M |
| Other Expenses | 0.00 | -6.00K | -2.00K | -2.00K | -2.00K | -3.00K | 2.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.37K | 0.00 | 85.72K | 0.00 | 0.00 | 0.00 | 115.45K | 100.00K | 100.00K | 100.00K | 0.00 |
| Operating Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.57M | 14.21M | 12.19M | 7.44M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.59M | 5.25M | 825.00K | 79.80K | 92.80K | 101.48K | 3.68M | 3.58M | 4.14M | 4.93M | 5.02M | 4.40M | 4.10M | 3.30M | 2.21M |
| Cost & Expenses | 12.12M | 13.25M | 13.65M | 15.67M | 14.92M | 14.73M | 12.88M | 8.18M | 198.00K | 196.00K | 259.00K | 401.00K | 630.00K | 583.00K | 6.97M | 5.44M | 955.00K | 79.80K | 92.80K | 101.48K | 4.54M | 4.58M | 5.11M | 5.88M | 5.91M | 5.40M | 5.00M | 4.10M | 2.94M |
| Interest Income | 0.00 | 0.00 | 9.00K | 21.00K | 87.00K | 118.00K | 95.00K | 0.00 | 3.00K | 3.00K | 10.00K | 8.00K | 11.00K | 0.00 | 0.00 | 0.00 | 33.00K | 4.36K | 5.37K | 1.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.00K | 0.00 | 3.00K | 112.00K | 0.00 | 95.00K | 1.74M | 3.00K | 3.00K | 10.00K | 8.00K | 25.00K | 27.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Depreciation & Amortization | 84.00K | 377.00K | 640.00K | 566.00K | 551.00K | 203.00K | 78.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 967.00K | 1.21M | 561.00K | 61.00K | 0.00 | 0.00 | 0.00 | 71.08K | 84.93K | 101.83K | 107.91K | 115.45K | 100.00K | 100.00K | 100.00K | 49.74K |
| EBITDA | -11.56M | -11.82M | -12.57M | -14.44M | -14.05M | -13.90M | -12.23M | -8.54M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | 384.00K | -3.90M | -3.61M | -218.00K | -79.80K | -92.80K | -101.48K | -99.79K | -443.03K | -418.80K | -1.05M | -1.91M | -1.81M | -1.10M | -1.00M | -600.00K |
| EBITDA Ratio | -2,423.48% | -880.25% | -1,237.73% | -10,649.66% | -1,974.23% | -2,223.84% | -2,573.49% | -1,146.70% | 61.70% | 54.10% | 3.36% | -546.77% | -5,058.33% | 0.00% | -208.40% | -170.11% | -33.90% | 0.00% | 0.00% | 0.00% | -18.08% | -10.86% | -24.66% | -50.88% | -54.95% | -23.81% | -42.11% | -17.65% | 9.25% |
| Operating Income | -11.64M | -11.90M | -12.63M | -15.53M | -14.21M | -14.10M | -12.41M | -7.61M | 319.00K | 231.00K | 9.00K | -339.00K | -618.00K | -583.00K | -5.10M | -5.63M | -312.00K | -79.80K | -92.80K | -101.48K | -779.68K | -503.74K | -1.15M | -2.02M | -1.93M | -1.20M | -1.20M | -700.00K | 206.23K |
| Operating Income Ratio | -2,441.09% | -880.25% | -1,244.33% | -10,709.66% | -2,001.83% | -2,256.32% | -2,589.77% | -1,320.83% | 61.70% | 54.10% | 3.36% | -546.77% | -5,150.00% | 0.00% | -272.98% | -444.16% | -48.52% | 0.00% | 0.00% | 0.00% | -20.74% | -12.35% | -29.13% | -52.20% | -48.28% | -28.57% | -31.58% | -20.59% | 6.55% |
| Total Other Income/Expenses | 73.00K | -6.00K | 7.00K | 525.00K | -496.00K | 115.00K | 97.00K | -2.70M | 3.00K | 3.00K | 10.00K | 8.00K | -14.00K | 27.00K | 24.00K | -20.00K | 33.00K | -199.20K | 0.00 | 0.00 | 679.90K | 24.23K | 24.23K | 56.84K | 56.84K | 625.51K | 500.00K | 0.00 | 839.12K |
| Income Before Tax | -11.57M | -11.91M | -12.62M | -15.00M | -14.71M | -13.99M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | -331.00K | -632.00K | -556.00K | -5.08M | -5.80M | -279.00K | 0.00 | 0.00 | 0.00 | -722.70K | -479.51K | -1.23M | -1.96M | -1.54M | -1.30M | -700.00K | 0.00 | 139.12K |
| Income Before Tax Ratio | -2,425.79% | -880.70% | -1,243.65% | -10,347.59% | -2,071.69% | -2,237.92% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | -533.87% | -5,266.67% | 0.00% | -271.70% | -457.41% | -43.39% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -50.73% | -38.72% | -30.95% | -18.42% | 0.00% | 4.42% |
| Income Tax Expense | 0.00 | 6.00K | -2.00K | 1.00K | 110.00K | -115.00K | -192.00K | 5.40M | -6.00K | -6.00K | -20.00K | -652.00K | -10.31M | 10.90M | -48.00K | 3.10M | 0.00 | -4.36K | 92.80K | 710.86K | -28.24K | -48.45K | 149.87K | 103.91K | -762.83K | 200.00K | -1.10M | -100.00K | 3.53K |
| Net Income | -11.57M | -11.91M | -12.62M | -15.01M | -14.82M | -13.87M | -12.31M | -10.31M | 322.00K | 234.00K | 19.00K | 305.00K | 9.66M | -11.51M | -5.08M | -5.80M | -287.00K | -75.44K | -92.80K | -812.34K | -722.70K | -479.51K | -1.23M | -2.18M | -1.54M | -1.30M | -600.00K | -600.00K | 135.60K |
| Net Income Ratio | -2,425.79% | -881.14% | -1,243.45% | -10,348.28% | -2,087.18% | -2,219.52% | -2,569.52% | -1,789.93% | 62.28% | 54.80% | 7.09% | 491.94% | 80,516.67% | 0.00% | -271.70% | -457.41% | -44.63% | 0.00% | 0.00% | 0.00% | -19.22% | -11.76% | -31.02% | -56.35% | -38.72% | -30.95% | -15.79% | -17.65% | 4.31% |
| EPS | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.91 | -275.16 | -237.12 | -210.36 | -97.17 | -117.32 | 0.38 |
| EPS Diluted | -8.19 | -10.08 | -11.19 | -22.24 | -39.38 | -48.80 | -43.54 | -166.33 | 27.86 | 20.50 | 1.78 | 28.61 | 906.29 | -1.08K | -528.72 | -742.35 | -34.84 | -8.21 | -10.10 | -98.42 | -92.38 | -61.30 | -156.15 | -275.16 | -237.12 | -204.63 | -97.17 | -113.64 | 0.38 |
| Weighted Avg Shares Out | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.82K | 7.92K | 6.51K | 6.18K | 6.18K | 5.11K | 360.60K |
| Weighted Avg Shares Out (Dil) | 1.41M | 1.18M | 1.13M | 674.58K | 376.29K | 284.28K | 282.67K | 61.99K | 11.56K | 11.41K | 10.66K | 10.66K | 10.66K | 10.66K | 9.60K | 7.81K | 8.24K | 9.19K | 9.19K | 8.25K | 7.82K | 7.82K | 7.86K | 7.92K | 6.51K | 6.35K | 6.18K | 5.28K | 360.60K |
BioCardia shares slide on disappointing interim data from heart therapy trial
BioCardia shares fell more than 20% in pre-market trade on Tuesday after the biopharmaceutical firm revealed that its Phase 3 trial of CardiAMP cell therapy for heart failure was unlikely to meet its three-tiered primary efficacy endpoint based on interim...
BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial
SUNNYVALE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced it has finalized external review of interim data and evaluated interim efficacy...
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.14 per share a year ago.
BioCardia, Inc. (BCDA) Q2 2023 Earnings Call Transcript
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President & Chief Executive Officer David McClung - Chief Financial Officer Conference Call Participants Joe...
BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly...
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
SUNNYVALE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and six months...
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified...
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency
SUNNYVALE, Calif. , July 05, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the CardiAMP Cell Therapy System to...
BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that FDA Center for Biologics Evaluation and Research (CBER) has completed review...
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: JP7282649B2...
Source: https://incomestatements.info
Category: Stock Reports